Clinical application of omalizumab in patients with chronic urticaria complicated with anaphylactic shock
10.3760/cma.j.cn112150-20240118-00067
- VernacularTitle:奥马珠单抗对慢性荨麻疹合并过敏性休克患者的应用研究
- Author:
Yusong GAO
1
;
Chengyue PENG
;
Zuotao ZHAO
Author Information
1. 北京大学第一医院急诊科，北京 100034
- Keywords:
Anaphylactic shock;
Omalizumab;
Chronic urticaria
- From:
Chinese Journal of Preventive Medicine
2024;58(3):325-330
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety evaluation of omalizumab in patients with chronic urticaria who are not well treated with antihistamine and have a history of anaphylactic shock.Methods:A retrospective observational real-world study was conducted in which patients with chronic urticaria who were admitted to Peking University First Hospital from November 2018 to January 2024 who were poorly treated with antihistamine drugs and had a history of anaphylactic shock were selected as the study subjects, and 300 mg of omalizumab was injected subcutaneously every 4 weeks, and the occurrence of UCT (urticaria control test), the number of occurrences of anaphylactic shock and other adverse events were recorded during the treatment.Results:Among the 11 patients who started omalizumab treatment for 3 months, 10 patients had complete control of chronic urticaria (UCT=16), 1 patient was partially controlled (UCT=15), and 9 patients did not have anaphylactic shock during follow-up (10 cases after 12 months of follow-up and 1 case after 2 months of follow-up). Two patients developed anaphylactic shock after omalizumab injection. In this study, during the follow-up period (2-38 months), 11 patients were well tolerated with omalizumab, of which 4 continued to use omalizumab for urticaria, 6 stopped using omalizumab due to good urticaria control and no recurrence of anaphylactic shock, and 1 was lost to follow-up.Conclusion:Omalizumab may have good efficacy and safety in patients with chronic urticaria who are poorly treated with antihistamines and have a history of anaphylactic shock, and may have a potential role in preventing anaphylactic shock.
